I didn’t get a chance to watch the June 5th FDA advisory committee meeting on the new vaccine formulation for Covid-19 for this fall. There is a nice summary on the Minnesota CIDRAP (Center for Infectious Disease Research & Policy).
The committee unanimously upvoted the selection of the JN.1 lineage strain (which includes JN.1, KP.2 etc) for Covid vaccines this fall in the U.S.
As usual, Director Dr. Jerry Weir’s slides (summary slides 22-26) provide excellent background and clear discussion.
There will be an FDA VRBPAC meeting on June 5, 2024, 8:30 a.m.-4:30 p.m. ET to discuss Covid vaccines for this fall.
The May FDA VRBPAC meeting on Covid vaccines, originally scheduled for this month has been rescheduled to June 5, 2024, 8:30 AM-4:30 PM EST.
The FDA Vaccines and Related Biological Products Advisory Committee will meet today from 8:30 am-5:00 pm ET to discuss and make recommendations on strain selection for the periodic updated Covid-19 vaccines for the 2023-2024 vaccine campaign.
The discussion topic will be:
“Based on the evidence and other considerations presented, please
discuss selection of a specific XBB lineage (e.g., XBB.1.5 or
XBB.1.16 or XBB.2.3) for inclusion in the 2023-2024 Formula of
COVID-19 vaccines in the U.S.”
The voting question will be:
“For the 2023-2024 Formula of COVID-19 vaccines in the U.S., does the
committee recommend a periodic update of the current vaccine composition to
a monovalent XBB-lineage?”
UPDATE: The committee upvoted the question unanimously. The word “periodic” was removed from the question. A September 2023 time frame was expected for availability of the new vaccine.
Go Retire Psychiatrist 